Nanthealth LLC (NYSE:NH) traded down 3.3% on Monday . The company traded as low as $12.30 and last traded at $12.37, with a volume of 53,572 shares traded. The stock had previously closed at $12.79.

A number of equities research analysts have recently weighed in on the company. First Analysis assumed coverage on Nanthealth in a report on Monday, June 27th. They set an “overweight” rating and a $18.00 target price for the company. Jefferies Group assumed coverage on Nanthealth in a report on Monday, June 27th. They set a “buy” rating for the company. FBR & Co reissued a “buy” rating on shares of Nanthealth in a report on Thursday. Canaccord Genuity assumed coverage on Nanthealth in a report on Monday, June 27th. They set a “buy” rating and a $17.00 target price for the company. Finally, Cowen and Company assumed coverage on Nanthealth in a report on Monday, June 27th. They set an “outperform” rating and a $19.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $18.00.

The company’s market cap is $1.49 billion. The company has a 50-day moving average price of $11.55 and a 200 day moving average price of $12.38.

Nanthealth (NYSE:NH) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.26. The company had revenue of $31.50 million for the quarter, compared to the consensus estimate of $23.55 million. The company’s quarterly revenue was up 166.9% compared to the same quarter last year. On average, equities analysts expect that Nanthealth LLC will post ($0.59) EPS for the current fiscal year.

In other Nanthealth news, major shareholder Healthcare Solution Allscripts acquired 714,286 shares of Nanthealth stock in a transaction on Tuesday, June 7th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $10,000,004.00. Following the purchase, the insider now directly owns 15,000,000 shares of the company’s stock, valued at $210,000,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Patrick Soon-Shiong acquired 357,143 shares of Nanthealth stock in a transaction on Tuesday, June 7th. The stock was acquired at an average price of $14.00 per share, with a total value of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.